Welcome to the international HTA database

Showing [16861 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Endovascular thermal ablation technologies for treatment of varicose veins: a review of clinical effectiveness, safety, cost-effectiveness, and guidelines
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Strengthening the evidence base for a learning health system - Inspirations from good practice for capacity building in health services research and public health research
2011	HAYES, Inc.	Implantable interStim neurostimulator (Medtronic Inc.) for sacral neuromodulation in treatment of fecal incontinence in children
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Combination therapy for pulmonary arterial hypertension: a review of the clinical effectiveness
2011	Institute for Clinical and Economic Review (ICER)	Management options for low back disorders
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis
2011	HAYES, Inc.	Mobile cardiac outpatient telemetry (MCOT) (CardioNet ambulatory ECG monitor; CardioNet Inc.) for home monitoring of cardiac patients
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs: a review of the clinical effectiveness, safety, and cost effectiveness
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Ipilimumab for pre-treated patients with advanced/metastatic melanoma
2011	HAYES, Inc.	Office-based phototherapy for treatment of atopic dermatitis in adults
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Nilotinib (Tasigna) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase
2011	HAYES, Inc.	Office-based phototherapy for treatment of atopic dermatitis in children
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Eliglustat tartrate, miglustat, imiglucerase, velaglucerase or a combination of these for the treatment of Gaucher disease: a review of clinical effectiveness and safety
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Cabazitaxel (Jevtana) for the second-line therapy of patients with hormone-refractory metastatic prostate cancer
2011	HAYES, Inc.	OptiVol fluid status monitoring system (Medtronic Inc.) for management of heart failure
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Triaging patients from the emergency department to other medical centres: a review of the clinical evidence and guidelines
2011	HAYES, Inc.	Portal vein embolization for liver regeneration followed by staged hepatectomy for cholangiocarcinoma
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Annual Report 2010. English version
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Functional Electric Stimulation (FES) for children with cerebral palsy: clinical effectiveness
2011	HAYES, Inc.	Provenge (Dendreon Corp.) vaccine for treatment of prostate cancer
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Blood glucose monitors and test strips: a review of the comparative clinical evidence and cost-effectiveness
2011	HAYES, Inc.	Relieva balloon sinuplasty (Acclarent Inc.) for treatment of chronic sinusitis
2011	NIHR Horizon Scanning Centre (NIHR HSC)	IRay™ for wet age related macular degeneration
2011	Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR)	Criteria for appropriate use of FDG-PET in esophageal cancer
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Dasatinib (Sprycel) for the first-line therapy of patients with newly diagnosed chronic phase philadelphia chromosome positive chronic myeloid leukemia.
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Umbilical cord clamp removal: a review of the clinical benefits and harms
2011	HAYES, Inc.	Sacroiliac joint fusion for treatment of adult low back pain
2011	Technology Assessment Unit of the McGill University Health Centre (MUHC)	X-ray versus gamma irradiation of blood components for prevention of transfusion-associated graft versus host disease: a brief report
2011	Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR)	Criteria for appropriate use of FDG-PET in colorectal cancer
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Non-stress testing for pregnant adults with diabetes
2011	HAYES, Inc.	Sensei X robotic catheter system (Hansen Medical Inc.) for treatment of atrial fibrillation
2011	Technology Assessment Unit of the McGill University Health Centre (MUHC)	The use of Lactobacillus probiotics in the prevention of antibiotic associated clostridium difficile diarrhea
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Surgical dressing for patients undergoing hip or knee arthroplasty: clinical effectiveness and cost-effectiveness
2011	HAYES, Inc.	SNaP wound care system (Spiracur Inc.) for treatment of lower extremity ulcers
2011	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Drug eluting stents. What should be the indications for their use at the MUHC?
2011	National Institute for Health and Care Excellence (NICE)	MiraQ for assessing graft flow during coronary artery bypass graft surgery. NICE medical technologies guidance 8
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Auditory screening and hearing loss prevention: a review of the clinical evidence and guidelines
2011	HAYES, Inc.	Tandem autologous peripheral blood stem cell transplantation for neuroblastoma
2011	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Subglottic secretion drainage endotracheal tubes for prevention of ventilator-associated pneumonia
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Upper extremity deep vein thrombosis with peripherally inserted central catheters: a review of the guidelines
2011	HAYES, Inc.	Ultroid hemorrhoid management system (Ultroid Technologies Inc.)
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Cardiac output monitors to assess patient resuscitation needs: a review of clinical effectiveness and cost-effectiveness
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Clopidogrel, Prasugrel and Ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Quality assessment of the Canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines in adults with ADHD
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Multidisciplinary medication review in long term care: a review of the clinical evidence and guidelines
2011	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Aortic valve bypass (apicoaortic conduit) in adult degenerative aortic stenosis
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Metabolic monitoring and interventions for reducing metabolic syndrome in patients treated with atypical antipsychotics: a review of the clinical evidence
2011	Health Technology and Policy Unit (HTPU)	Middle ear implants for the treatment of hearing loss
2011	Scottish Health Technologies Group (SHTG)	Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Facet joint injection as diagnostic and therapeutic tools for pain of the cervical and lumbar spine: a review of clinical and cost-effectiveness
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines
2011	Health Technology and Policy Unit (HTPU)	Photodynamic therapy for skin cancer & pre-cancerous skin conditions
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Management and patient safety of IVIG administration: a review of clinical practice guidelines
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	T-score as a measurement to assess the 10-year fracture risk: a review of the clinical evidence
2011	HTA Unit, University of Calgary	Health technology reassessment and reinvestment: a systematic review of current practices
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pediatric supraglottic airway devices: a review of clinical effectiveness
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Adrenal suppression and clinical harms by inhaled corticosteroids: a review of safety and guidelines
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Robotic surgery versus open-chest surgery for internal mammary artery harvesting and mitral valve surgery: clinical effectiveness
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Acetylsalicylic acid for venous thromboembolism prophylaxis: a review of clinical evidence, benefits and harms
2011	Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR)	In vitro test for the evaluation of individual risk of metastasis in surgically treated women for breast cancer
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Feeding tube verification procedures: optimal timing and guidelines
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Phallometric assessment of sex offenders: a review of the clinical evidence and guidelines
2011	NIHR Health Technology Assessment programme	Conservative treatment for urinary incontinence in Men After Prostate Surgery (MAPS): two parallel randomised controlled trials
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Non-adherent versus traditional dressings for wound care: comparative effectiveness, safety, and guidelines
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Suboxone for short-term detoxification: a review of the clinical evidence
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intravenous insulin infusions in labouring women: guidelines
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Combination Benzodiazepine-Opioid use: a review of the evidence on safety
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of fentanyl and continuous electronic fetal monitoring in labour and delivery: a review of clinical effectiveness, safety, and clinical practice guidelines
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Enzyme replacement therapy for rare diseases: a review of clinical efficacy
2011	NIHR Health Technology Assessment programme	Liraglutide for the treatment of type 2 diabetes
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Antiviral stockpiling strategies for pandemic influenza: a review of the clinical and cost-effectiveness
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacological and non-pharmacological therapies for adults with attention-deficit/hyperactivity disorder: systematic review and meta-analysis of clinical evidence
2011	NIHR Health Technology Assessment programme	Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Facet joint injection as diagnostic and therapeutic tools for pain of the cervical and lumbar spine: a review of clinical and cost-effectiveness
2011	NIHR Health Technology Assessment programme	Golimumab for the treatment of ankylosing spondylitis
2011	Agency for Healthcare Research and Quality (AHRQ)	Therapies for children with autism spectrum disorders.
2011	NIHR Health Technology Assessment programme	An evidence synthesis of qualitative and quantitative research on component intervention techniques, effectiveness, cost-effectiveness, equity and acceptability of different versions of health-related lifestyle advisor role in improving health
2011	NIHR Health Technology Assessment programme	Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
2011	Agency for Healthcare Research and Quality (AHRQ)	Oral diabetes medications for adults with type 2 diabetes: an update
2011	NIHR Health Technology Assessment programme	Bivalirudin for the treatment of ST-segment elevation myocardial infarction
2011	NIHR Health Technology Assessment programme	Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation
2011	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation
2011	Adelaide Health Technology Assessment (AHTA)	Brachytherapy for the treatment of prostate cancer
2011	NIHR Health Technology Assessment programme	Ticagrelor for the treatment of acute coronary syndromes
2011	Health Council of the Netherlands Gezondheidsraad (GR)	Treating the effect of child abuse
2011	NIHR Health Technology Assessment programme	Eribulin for the treatment of locally advanced or metastatic breast cancer
2011	Health Council of the Netherlands Gezondheidsraad (GR)	Guidelines for a healthy diet: the ecological perspective
2011	NIHR Health Technology Assessment programme	Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation
2011	NIHR Health Technology Assessment programme	Fingolimod for the treatment of relapsing remitting multiple sclerosis
2011	NIHR Health Technology Assessment programme	Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
2011	NIHR Health Technology Assessment programme	VenUS III: a randomised controlled trial of therapeutic ultrasound in the management of venous leg ulcers
2011	NIHR Health Technology Assessment programme	Denosumab for osteoporotic fractures in post menopausal women primary and secondary prevention
2011	Medical Advisory Secretariat (MAS)	Corneal collagen cross-linking using riboflavin and ultraviolet-A for corneal thinning disorders
2011	NIHR Health Technology Assessment programme	Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing therapy
2011	NIHR Health Technology Assessment programme	Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
2011	The Swedish Council on Health Technology Assessment (SBU)	Treatment of hemophilia A and B and von willebrand disease
2011	Agency for Healthcare Research and Quality (AHRQ)	Screening and treatment of subclinical hypothyroidism or hyperthyroidism
2011	NIHR Health Technology Assessment programme	A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study)